Growth hormone deficiency epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
 
(6 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
[[Prevalence]] and [[incidence]] data of growth hormone deficiency vary widely due to the lack of standard diagnostic criteria. Diagnosis of growth hormone deficiency is made during 2 broad age peaks; the first age peak occurs at 5 years. The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years. There is no apparent racial difference in the incidence of GHD. Seventy-three percent of patients with idiopathic GHD in were males due to societies that concern more about males short stature than the females. Patients with GHD from organic causes such as [[Tumor|tumors]] and [[Radiation therapy|radiation,]] in which no gender bias should be present, were still 62% male.
[[Prevalence]] and [[incidence]] data of growth hormone deficiency vary widely due to the lack of standard diagnostic criteria. Diagnosis of growth hormone deficiency is made during 2 broad age peaks; the first age peak occurs at 5 years. The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years. There is no apparent racial difference in the incidence of GHD. In societies that concern more about male short stature than the females, 73% of males were found to have idiopathic GHD. When GHD is caused from organic causes such as [[Tumor|tumors]] and [[Radiation therapy|radiation,]] in which no gender bias should be present, there was still 62% male.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence<ref name="pmid16166753">{{cite journal| author=Erfurth EM| title=Epidemiology of adult growth hormone deficiency. Prevalence, incidence, mortality and morbidity. | journal=Front Horm Res | year= 2005 | volume= 33 | issue=  | pages= 21-32 | pmid=16166753 | doi=10.1159/000088397 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16166753  }}</ref>===
===Incidence===
* [[Prevalence]] and [[incidence]] data vary widely due to the lack of standard diagnostic criteria.
* [[Prevalence]] and [[incidence]] data vary widely due to the lack of standard diagnostic criteria.<ref name="pmid16166753">{{cite journal| author=Erfurth EM| title=Epidemiology of adult growth hormone deficiency. Prevalence, incidence, mortality and morbidity. | journal=Front Horm Res | year= 2005 | volume= 33 | issue=  | pages= 21-32 | pmid=16166753 | doi=10.1159/000088397 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16166753  }}</ref>
 
* The [[incidence]] of persistent GHD is 12.0%.<ref name="pmid25301482">{{cite journal| author=Smyczyńska J, Stawerska R, Lewiński A, Hilczer M| title=Incidence and predictors of persistent growth hormone deficiency (GHD) in patients with isolated, childhood-onset GHD. | journal=Endokrynol Pol | year= 2014 | volume= 65 | issue= 5 | pages= 334-41 | pmid=25301482 | doi=10.5603/EP.2014.0046 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25301482  }}</ref>
* The [[incidence]] of persistent GHD was 12.0%.<ref name="pmid25301482">{{cite journal| author=Smyczyńska J, Stawerska R, Lewiński A, Hilczer M| title=Incidence and predictors of persistent growth hormone deficiency (GHD) in patients with isolated, childhood-onset GHD. | journal=Endokrynol Pol | year= 2014 | volume= 65 | issue= 5 | pages= 334-41 | pmid=25301482 | doi=10.5603/EP.2014.0046 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25301482  }}</ref>
* There is no significant difference in the [[incidence]] of [[Pituitary gland|pituitary hypoplasia]] between the patients with persistent and transient GHD.
* There is no significant difference in the [[incidence]] of [[Pituitary gland|pituitary hypoplasia]] between the patients with persistent and transient GHD.


=== Gender ===
=== Gender ===
*Seventy-three percent of patients with [[idiopathic]] GHD in were males due to societies that care a lot about males short stature than the females.<ref name="pmid10393494">{{cite journal| author=Finkelstein BS, Singh J, Silvers JB, Marrero U, Neuhauser D, Cuttler L| title=Patient attitudes and preferences regarding treatment: GH therapy for childhood short stature. | journal=Horm Res | year= 1999 | volume= 51 Suppl 1 | issue=  | pages= 67-72 | pmid=10393494 | doi=53138 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10393494  }}</ref>
*Seventy-three percent of patients with [[idiopathic]] GHD occur in societies that care a lot about short stature of males more than females.<ref name="pmid10393494">{{cite journal| author=Finkelstein BS, Singh J, Silvers JB, Marrero U, Neuhauser D, Cuttler L| title=Patient attitudes and preferences regarding treatment: GH therapy for childhood short stature. | journal=Horm Res | year= 1999 | volume= 51 Suppl 1 | issue=  | pages= 67-72 | pmid=10393494 | doi=53138 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10393494  }}</ref>
*Patients with GHD from organic causes such as [[tumors]] and [[Radiation therapy|radiation]], in which no gender bias should be present, were still 62% male.
*Prevalence of GHD from organic causes such as [[tumors]] and [[Radiation therapy|radiation]] is 62% male.  
*Cuttler et al published results of a survey of pediatric endocrinologists that [[growth hormone]] treatment was 1.3 times more common in boys than in girls.<ref name="pmid21229093">{{cite journal| author=Schnell FN, Bannard JR| title=Short Stature in Childhood and Adolescence: Part 1: Medical management. | journal=Can Fam Physician | year= 1991 | volume= 37 | issue=  | pages= 2206-13 | pmid=21229093 | doi= | pmc=2145710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21229093  }}</ref>  
*A survey of pediatric endocrinologists show that [[growth hormone]] treatment was 1.3 times more common in boys than in girls.<ref name="pmid21229093">{{cite journal| author=Schnell FN, Bannard JR| title=Short Stature in Childhood and Adolescence: Part 1: Medical management. | journal=Can Fam Physician | year= 1991 | volume= 37 | issue=  | pages= 2206-13 | pmid=21229093 | doi= | pmc=2145710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21229093  }}</ref>  


==== Age ====
==== Age ====
*Diagnosis of growth hormone deficiency is made during 2 broad age peaks; the first age peak occurs at 5 years, a time when children begin school.   
*Growth hormone deficiency has a bimodal distribution; the first age peak occurs at 5 years.   
*The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years.  
*The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years.  
*While congenital GHD and most cases of idiopathic GHD are thought to be present from birth, diagnosis is often delayed until the patient’s short stature is noticed in relation to their peers.   
*Congenital GHD and most cases of idiopathic GHD are thought to be present from birth, diagnosis is often delayed until the patient’s short stature is noticed in relation to their peers.   


==== Race ====
==== Race ====
*There is no apparent racial difference in the incidence of GHD.
*There is no racial predilection of growth hormone deficiency.


==References==
==References==

Latest revision as of 14:37, 25 October 2017

Growth hormone deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Growth hormone deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Growth hormone deficiency epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Growth hormone deficiency epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Growth hormone deficiency epidemiology and demographics

CDC on Growth hormone deficiency epidemiology and demographics

Growth hormone deficiency epidemiology and demographics in the news

Blogs on Growth hormone deficiency epidemiology and demographics

Directions to Hospitals Treating Growth hormone deficiency

Risk calculators and risk factors for Growth hormone deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Prevalence and incidence data of growth hormone deficiency vary widely due to the lack of standard diagnostic criteria. Diagnosis of growth hormone deficiency is made during 2 broad age peaks; the first age peak occurs at 5 years. The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years. There is no apparent racial difference in the incidence of GHD. In societies that concern more about male short stature than the females, 73% of males were found to have idiopathic GHD. When GHD is caused from organic causes such as tumors and radiation, in which no gender bias should be present, there was still 62% male.

Epidemiology and Demographics

Incidence

Gender

  • Seventy-three percent of patients with idiopathic GHD occur in societies that care a lot about short stature of males more than females.[3]
  • Prevalence of GHD from organic causes such as tumors and radiation is 62% male.
  • A survey of pediatric endocrinologists show that growth hormone treatment was 1.3 times more common in boys than in girls.[4]

Age

  • Growth hormone deficiency has a bimodal distribution; the first age peak occurs at 5 years.
  • The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years.
  • Congenital GHD and most cases of idiopathic GHD are thought to be present from birth, diagnosis is often delayed until the patient’s short stature is noticed in relation to their peers.

Race

  • There is no racial predilection of growth hormone deficiency.

References

  1. Erfurth EM (2005). "Epidemiology of adult growth hormone deficiency. Prevalence, incidence, mortality and morbidity". Front Horm Res. 33: 21–32. doi:10.1159/000088397. PMID 16166753.
  2. Smyczyńska J, Stawerska R, Lewiński A, Hilczer M (2014). "Incidence and predictors of persistent growth hormone deficiency (GHD) in patients with isolated, childhood-onset GHD". Endokrynol Pol. 65 (5): 334–41. doi:10.5603/EP.2014.0046. PMID 25301482.
  3. Finkelstein BS, Singh J, Silvers JB, Marrero U, Neuhauser D, Cuttler L (1999). "Patient attitudes and preferences regarding treatment: GH therapy for childhood short stature". Horm Res. 51 Suppl 1: 67–72. doi:53138 Check |doi= value (help). PMID 10393494.
  4. Schnell FN, Bannard JR (1991). "Short Stature in Childhood and Adolescence: Part 1: Medical management". Can Fam Physician. 37: 2206–13. PMC 2145710. PMID 21229093.

Template:WH Template:WS